New combo therapy aims to shrink tough lung tumors

NCT ID NCT06623136

Recruiting now Disease control Sponsor: Elpiscience (Suzhou) Biopharma, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental drug (ES102) to an approved immunotherapy (toripalimab) can shrink tumors in people with advanced non-small cell lung cancer that has not responded to prior treatment. About 40 adults aged 18-75 will receive the combination and be monitored for tumor response and side effects. The goal is to improve disease control, not to cure the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Beijing Chest Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, China
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital)
NOT_YET_RECRUITING

Jinan, Shandong, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Jilin Cancer Hospital
RECRUITING

Changchun, Jilin, China
Shanxi Provincial Cancer Hospital
RECRUITING

Taiyuan, China
Taizhou Hospital
RECRUITING

Taizhou, China
The First Affiliated Hospital of He'nan University of Science and Technology
RECRUITING

Luoyang, China
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.